RA0260

antibody from Oursmab

Targeting: FOLR1 FOLR, FRα

Western blot (Data presented on provider website)

ELISA (Data presented on provider website)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0260

Provider

Oursmab

Product name

Farletuzumab (Biosimilar Reference Antibody) (FOLR1)

Antibody type

Monoclonal

Description

Farletuzumab (development code MORAb-003) is a humanized monoclonal IgG1 antibody developed for the treatment of ovarian cancer. It functions as a targeted therapy against a folate receptor highly expressed on ovarian cancer cells. The antibody is engineered with a modified Fc region to enhance antibody-dependent cellular cytotoxicity (ADCC), a key mechanism for killing cancer cells. By binding to its target on the tumor cell surface, farletuzumab marks the cells for destruction by immune effector cells, primarily natural killer (NK) cells. It was also investigated for its potential to directly inhibit tumor-promoting signaling pathways and to deliver cytotoxic payloads in antibody-drug conjugate (ADC) formats.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.